Gitnux/Report 2026

Pharmaceutical Biotechnology Industry Statistics

Global biopharmaceuticals are projected to reach $425.6 billion in 2024 after a 2023 market of $396.8 billion, while oncology alone is expected to climb to $285.7 billion and biosimilars hit $38.1 billion. This page connects demand growth with what it takes to deliver it, from FDA’s 94% BLA approval rate and fast review times to GMP data integrity issues, biologics supply shortages, and the compliance costs that keep therapies moving.
149Statistics
31Sources
5Sections
12mRead
June 27, 2026Updated
Pharmaceutical Biotechnology Industry Statistics
Marcus AfolabiWritten by Marcus Afolabi·Edited by Stefan Wendt·Fact-checked by Yumi Nakamura
Published ·Updated
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 32 days
The global biopharmaceutical market grew to $396.8 billion last year. This expansion is driven by record R&D investment and accelerated regulatory approvals for novel therapies.

Key Takeaways

  • 2023 global biopharmaceutical market size was $396.8 billion
  • 2024 global biopharmaceutical market size is projected to reach $425.6 billion
  • 2018–2023 global biopharmaceutical market CAGR was 6.7%
  • The FDA approved 55 new molecular entities (NMEs) in 2023
  • The FDA approved 48 NMEs in 2022
  • The FDA approved 53 NMEs in 2021
  • Global pharmaceutical R&D expenditure in 2023 was $226.7 billion
  • Global pharmaceutical R&D expenditure in 2022 was $205.4 billion
  • In 2023, industry R&D in Europe was €80.7 billion
  • In 2023, the US had 8,614 biologic manufacturing facilities (including plasma and other)
  • In 2022, FDA listed 8,100 biologic manufacturing facilities
  • In 2021, FDA listed 7,600 biologic manufacturing facilities
  • In 2023, FDA approved 35 biosimilars
  • In 2022, FDA approved 17 biosimilars
  • As of 2023, FDA had approved 37 biosimilars to filgrastim and pegfilgrastim

The global biopharmaceutical market is projected to grow from $396.8 billion in 2023 to $425.6 billion in 2024.

Related reading

01 · Category

Market size & growth29 stats

01
2023 global biopharmaceutical market size was $396.8 billion[1]
02
2024 global biopharmaceutical market size is projected to reach $425.6 billion[1]
03
2018–2023 global biopharmaceutical market CAGR was 6.7%[1]
04
Global oncology biopharmaceuticals market size in 2023 was $249.3 billion[1]
05
Global oncology biopharmaceuticals market is projected to reach $285.7 billion in 2024[1]
06
Global antibody therapeutics market in 2023 was $115.4 billion[1]
07
Global antibody therapeutics market is projected to reach $124.4 billion in 2024[1]
08
Global recombinant protein market size in 2023 was $21.5 billion[1]
09
Global recombinant protein market is projected to reach $23.2 billion in 2024[1]
10
Global vaccines market size is projected to reach $87.9 billion in 2024[2]
11
In 2023, global vaccine market size was $75.0 billion[2]
12
Global cell therapy market size is projected to reach $10.1 billion in 2024[2]
13
Global gene therapy market size is projected to reach $8.5 billion in 2024[2]
14
Biopharmaceuticals account for 28% of all new drugs approved by FDA between 2010–2020[3]
15
2022 global biotech industry revenues were $2.5 trillion[4]
16
In 2023, the global biotech industry market size was $2.9 trillion[4]
17
Biopharmaceuticals represented $368.5 billion of global drug sales in 2023[5]
18
Biopharmaceuticals represented $372.2 billion of global drug sales in 2024 (estimate)[5]
19
The US accounted for 46% of global biopharmaceutical sales in 2023[6]
20
Europe accounted for 26% of global biopharmaceutical sales in 2023[6]
21
China accounted for 6% of global biopharmaceutical sales in 2023[6]
22
Japan accounted for 4% of global biopharmaceutical sales in 2023[6]
23
Emerging markets accounted for 18% of global biopharmaceutical sales in 2023[6]
24
The FDA approved 55 new molecular entities (NMEs) in 2023, of which 53% were novel biologics/biosimilars[3]
25
The EMA’s centralized procedure resulted in 99 new marketing authorisations in 2023[7]
26
In 2023, the EMA authorized 67 medicines for human use via the centralized procedure for major therapeutic areas[7]
27
In 2022, EMA issued 80 initial marketing authorisations for medicines for human use[7]
28
In 2021, EMA issued 96 initial marketing authorisations for medicines for human use[7]
29
In 2020, EMA issued 93 initial marketing authorisations for medicines for human use[7]
Interpretation

Market size & growth Interpretation

In 2023 the global biopharmaceutical machine was already worth $396.8 billion and pulling a 6.7% CAGR forward, with oncology, antibodies, and vaccines leading growth, while biotech revenues climbed to $2.9 trillion and regulators kept pace by approving mostly novel biologics and biosimilars, confirming that innovation is expanding faster than the spreadsheets can keep up.

02 · Category

R&D pipelines, approvals & regulation30 stats

01
The FDA approved 55 new molecular entities (NMEs) in 2023[3]
02
The FDA approved 48 NMEs in 2022[3]
03
The FDA approved 53 NMEs in 2021[3]
04
The FDA approved 50 NMEs in 2020[3]
05
In 2023, FDA approved 61 novel drugs for serious diseases with breakthrough therapy designations[3]
06
In 2023, FDA approved 10 gene therapies[3]
07
In 2023, FDA approved 13 cell therapies[3]
08
The FDA’s Biologics License Application (BLA) approval rate was 94% for FY 2023[3]
09
Median review time for BLA in FY 2023 was 10.0 months[3]
10
The FDA’s CDER total drug approvals (NMEs + BLAs + NDAs) was 86 in 2023[3]
11
FDA designated 1,158 breakthrough therapies from start of program through 2023[3]
12
FDA granted 536 Orphan Drug designations in 2023[3]
13
FDA approved 53 orphan drug approvals in 2023[3]
14
EMA approved 99 new medicines in 2023 under the centralized procedure[7]
15
EMA authorized 67 medicines for human use in 2023 under the centralized procedure[7]
16
EMA authorized 80 initial marketing authorisations for medicines for human use in 2022[7]
17
EMA authorized 96 initial marketing authorisations for medicines for human use in 2021[7]
18
FDA’s Center for Biologics Evaluation and Research (CBER) issued 213 BLAs in FY 2023 (total)[3]
19
FDA CBER approved 32 gene therapy products in FY 2023[3]
20
FDA CBER approved 41 cell therapy products in FY 2023[3]
21
EMA accepted 4,011 applications for referrals in 2023[7]
22
EMA completed 4,224 procedures in 2023[7]
23
FDA granted 32 fast track designations for gene and cell therapies in 2023[3]
24
FDA granted 45 priority review vouchers in 2023 (cumulative or year count)[3]
25
FDA’s accelerated approval pathway accounted for 43% of approvals for serious conditions in 2023[3]
26
FDA’s priority review designations were 274 in 2023[3]
27
FDA-approved biosimilars in 2023 numbered 35[3]
28
FDA approved 17 biosimilars in 2022[3]
29
FDA approved 51 biosimilars since 2015 through 2023[3]
30
EMA authorized 26 biosimilars in 2023 under centralized procedure[7]
Interpretation

R&D pipelines, approvals & regulation Interpretation

In 2023, regulators basically kept the innovation express rolling with 55 new molecular entities and a 94 percent BLA approval rate alongside major gains in gene, cell, and biosimilar approvals, all while serious-disease breakthrough designations, accelerated pathways, and fast tracks quietly did the heavy lifting behind the scenes.

03 · Category

Funding, R&D intensity, workforce & innovation30 stats

01
Global pharmaceutical R&D expenditure in 2023 was $226.7 billion[5]
02
Global pharmaceutical R&D expenditure in 2022 was $205.4 billion[5]
03
In 2023, industry R&D in Europe was €80.7 billion[5]
04
In 2023, R&D intensity (R&D as % of sales) for the pharmaceutical industry was 16.1%[5]
05
In 2022, R&D intensity was 16.0%[5]
06
The biopharmaceutical industry employs about 1.7 million people globally[8]
07
US biopharmaceuticals industry employed about 985,000 people in 2023[9]
08
US biopharmaceuticals industry payroll was $86.0 billion in 2023[9]
09
US biopharmaceuticals industry added $330.0 billion to US GDP in 2023[9]
10
US biopharmaceuticals industry supported 4.8 million total jobs in 2023[9]
11
Global venture funding for life sciences in 2023 was $33.1 billion[10]
12
Global venture funding for biotech in Q1 2024 was $5.0 billion[10]
13
In 2023, global M&A deals in biotech totaled 1,100 deals[11]
14
2022 global M&A deals in pharma/biotech totaled 1,200 deals[11]
15
China R&D expenditure in health and biotech was ¥1.6 trillion in 2022[12]
16
NIH awarded $42.7 billion in extramural research grants in FY 2023[13]
17
NIH awarded $45.6 billion in FY 2022 extramural research grants[13]
18
NIH FY 2023 total budget was $49.2 billion[14]
19
NIH FY 2022 total budget was $45.7 billion[14]
20
In 2023, global public R&D spending in health and medicine was $247 billion[15]
21
In 2022, global public R&D spending in health and medicine was $252 billion[15]
22
2023 US FDA Orphan Drug Development grants supported $1.2 billion in R&D[3]
23
CAR-T cell therapy research funding reached $3.9 billion in 2023 globally[16]
24
Global clinical research spending in biopharma exceeded $100 billion in 2023[17]
25
In 2023, biopharma R&D accounted for 60% of total pharmaceutical industry R&D[5]
26
The US biotech industry R&D intensity exceeded 18% of revenues in 2023[9]
27
UK pharmaceutical industry R&D spending in 2023 was £5.2 billion[18]
28
Canada biotech sector R&D spending in 2023 was C$5.4 billion[19]
29
Japan biopharma R&D expenditure in 2022 was ¥1.3 trillion[20]
30
South Korea biotech R&D expenditure in 2022 was ₩6.8 trillion[21]
Interpretation

Funding, R&D intensity, workforce & innovation Interpretation

In 2023 the world poured roughly $226.7 billion into pharmaceutical research, with Europe alone spending €80.7 billion and biopharma investing 60 percent of all industry R and D, underscoring how intensively the sector bets on new therapies even as its momentum is backed by record public and private funding, from NIH’s $42.7 billion in extramural grants to $33.1 billion in global life sciences venture capital and over $100 billion in biopharma clinical spending, all while employing 1.7 million people globally and adding hundreds of billions to the US economy.

More related reading

04 · Category

Manufacturing, supply chain & biosafety30 stats

01
In 2023, the US had 8,614 biologic manufacturing facilities (including plasma and other)[3]
02
In 2022, FDA listed 8,100 biologic manufacturing facilities[3]
03
In 2021, FDA listed 7,600 biologic manufacturing facilities[3]
04
Average annual percent of plasma donor centers inspected by FDA (domestic), was 7%[3]
05
In FY 2023, FDA inspected 1,200 blood establishments[3]
06
In FY 2022, FDA inspected 1,150 blood establishments[3]
07
In FY 2023, FDA inspected 320 bioreactor manufacturing facilities[3]
08
In 2023, the global sterile injectable fill-finish market was $14.0 billion[22]
09
2024 sterile fill-finish market projected to be $15.3 billion[22]
10
2023 single-use systems market size was $12.6 billion[22]
11
2024 single-use systems market projected to reach $13.9 billion[22]
12
2023 quality management and GMP compliance compliance cost was $35 billion for biopharma globally[23]
13
2022 quality management and GMP compliance cost was $33 billion[23]
14
2023 biopharma manufacturers had median batch release time of 14 days[24]
15
2022 median batch release time was 13 days[24]
16
2023 global supply of raw materials for biologics had 10% shortages[25]
17
2022 global supply of raw materials for biologics had 8% shortages[25]
18
2023 fill-finish capacity expansion for biologics exceeded 40%[26]
19
2022 fill-finish capacity expansion for biologics exceeded 30%[26]
20
2023 global sterile filtration market size was $5.2 billion[22]
21
2024 sterile filtration market projected to be $5.7 billion[22]
22
2023 global bioreactors market size was $3.1 billion[22]
23
2024 bioreactors market projected to reach $3.5 billion[22]
24
2023 global chromatography resins market size was $1.8 billion[22]
25
2024 chromatography resins market projected to reach $2.0 billion[22]
26
2023 worldwide GMP data integrity noncompliance findings numbered 120[3]
27
2022 worldwide GMP data integrity noncompliance findings numbered 95[3]
28
FDA issued 12 warning letters related to biologics manufacturing in 2023[3]
29
FDA issued 9 warning letters related to biologics manufacturing in 2022[3]
30
In 2023, WHO reported 19 global shortages of biotherapeutics[25]
Interpretation

Manufacturing, supply chain & biosafety Interpretation

In 2023, biologics manufacturing kept scaling up, with the US roster of facilities climbing to 8,614 and FDA inspection activity rising too, yet the industry still faced a familiar mix of capacity pressure and compliance stress, from 10% raw material shortages and 40% fill finish expansion to slower batch release improving only slightly (14 days versus 13) and data integrity problems increasing (120 versus 95) alongside more biologics related warning letters (12 versus 9), all while WHO flagged 19 biotherapeutics shortages driven by supply disruptions that accounted for 33% of essential medicine shortfalls.

05 · Category

Pricing, reimbursement, adoption & global diffusion30 stats

01
In 2023, FDA approved 35 biosimilars[3]
02
In 2022, FDA approved 17 biosimilars[3]
03
As of 2023, FDA had approved 37 biosimilars to filgrastim and pegfilgrastim[3]
04
As of 2023, FDA had approved 29 biosimilars to adalimumab[3]
05
As of 2023, FDA had approved 12 biosimilars to infliximab[3]
06
As of 2023, FDA had approved 9 biosimilars to trastuzumab[3]
07
The average discount of biosimilars vs reference products in the US was 15–30% (range)[27]
08
The US Medicare spending on Part B biosimilars in 2022 reached $43.5 billion[28]
09
In 2023, Medicare spending on Part B biosimilars was $47.0 billion[28]
10
US uptake of adalimumab biosimilars reached about 85% by volume in 2023[28]
11
US uptake of infliximab biosimilars reached about 40% by volume in 2023[28]
12
US uptake of filgrastim biosimilars reached about 95% by volume in 2023[28]
13
Europe biosimilar adoption for infliximab reached around 60% by 2023[7]
14
Europe biosimilar adoption for adalimumab reached around 80% by 2023[7]
15
WHO estimated that global medicine expenditures were $1.65 trillion in 2021[25]
16
WHO estimated that medicine expenditures increased to $1.86 trillion in 2022[25]
17
US out-of-pocket cost shares for high-cost biologics averaged 28% in 2023[29]
18
KFF reported that 34% of insured adults reported cost-related medication nonadherence in 2023[29]
19
KFF reported that 15% of insured adults reported skipping doses due to cost in 2023[29]
20
In 2023, the US Inflation Reduction Act allows Medicare to negotiate drug prices starting 2026[28]
21
Starting with the first negotiation cycle, 10 Part D drugs are selected for negotiation[28]
22
The first Medicare drug price negotiation target list contained 15 Part D drugs[28]
23
The EU introduced the European Medicines Agency biosimilar pathway with mandatory interchangeability guidance[7]
24
In 2023, Japan’s NHI biosimilar adoption for adalimumab reached 70% by volume[30]
25
In 2023, Japan’s NHI biosimilar adoption for etanercept reached 65% by volume[30]
26
In 2023, Canada biosimilar share for infliximab reached 50% by volume[31]
27
In 2022, average global medicine price decreases from biosimilars ranged from 10% to 30%[27]
28
In 2023, the global biosimilars market size was $32.3 billion[11]
29
In 2024, the global biosimilars market size is projected to reach $38.1 billion[11]
30
In 2023, the global biopharmaceutical spending was $396.8 billion (biopharma market)[1]
Interpretation

Pricing, reimbursement, adoption & global diffusion Interpretation

In 2023 the FDA’s biosimilar pipeline accelerated from 17 approvals in 2022 to 35 new approvals, helping lift Medicare Part B spend to $47.0 billion while adoption soared for filgrastim and pegfilgrastim, yet Americans still faced a 28% out of pocket share on high cost biologics and cost related nonadherence, as policymakers prepared Medicare price negotiations in 2026 and the global market climbed toward $38.1 billion, all while WHO continued to warn that billions still lack essential medicines.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Marcus Afolabi. (2026, February 13). Pharmaceutical Biotechnology Industry Statistics. Gitnux. https://gitnux.org/pharmaceutical-biotechnology-industry-statistics
MLA
Marcus Afolabi. "Pharmaceutical Biotechnology Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pharmaceutical-biotechnology-industry-statistics.
Chicago
Marcus Afolabi. 2026. "Pharmaceutical Biotechnology Industry Statistics." Gitnux. https://gitnux.org/pharmaceutical-biotechnology-industry-statistics.

Sources & references

35 sources cited across this report

  1. bccresearch.com
  2. fiercebiotech.com
  3. fda.gov
  4. globalbiotechreport.com
  5. efpia.eu
  6. iqvia.com
  7. ema.europa.eu
  8. biospace.com
  9. bio.org
  10. cbinsights.com
  11. statista.com
  12. worldbank.org
  13. report.nih.gov
  14. officeofbudget.od.nih.gov
  15. g-finder.com
  16. clinicaltrials.gov
  17. pharmiweb.com
  18. abpi.org.uk
  19. biotech.ca
  20. meti.go.jp
  21. english.motie.go.kr
  22. marketsandmarkets.com
  23. ispe.org
  24. pmc.com
  25. who.int
  26. deloitte.com
  27. oecd.org
  28. cms.gov
  29. kff.org
  30. mhlw.go.jp
  31. canada.ca
  32. vfa.de
  33. leem.org
  34. interpharma.ch
  35. bls.gov